Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931741 | 0.94 | CYP1A2 (0.50) | CYP1A2PPARDNR1I2PGRADORA3 | |
| SCHEMBL4232740 | 0.93 | CYP1A2 (0.48) | CYP1A2PPARDTSHRGAAALDH1A1 | |
| SCHEMBL8551385 | 0.93 | CYP1A2 (0.48) | CYP1A2PPARDTSHRGAAALDH1A1 | |
| SCHEMBL1406274 | 0.93 | CYP1A2 (0.48) | CYP1A2PPARDTSHRGAAALDH1A1 | |
| SCHEMBL18590888 | 0.93 | CYP1A2 (0.48) | CYP1A2PPARDTSHRGAAALDH1A1 | |
| SCHEMBL710885 | 0.88 | PPARD (0.54) | CYP1A2PPARDNR1I2PGRADORA3 | |
| SCHEMBL15951772 | 0.87 | DGKA (0.47) | CYP1A2PPARDTSHRDGKALPAR6 | |
| SCHEMBL2356490 | 0.87 | CYP1A2 (0.47) | CYP1A2PPARDNR1I2PGRADORA3 | |
| SCHEMBL2350461 | 0.86 | DGKA (0.46) | CYP1A2CYP3A4DGKALPAR6LPAR1 | |
| SCHEMBL15951716 | 0.86 | DGKA (0.50) | PPARDALDH1A1DGKALPAR6LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080573-A | Flame-retardant phenolic aldehyde/glass fiber composite board, preparation method and application | — | 2026-05-26 | — | — | CN | claimed |
| CN-122080573-A | Flame-retardant phenolic aldehyde/glass fiber composite board, preparation method and application | — | 2026-05-26 | — | — | CN | disclosed |
| CN-120895758-A | Electrolyte with phosphonate as organic additive and water-based zinc ion battery | 中国科学院福建物质结构研究所 | 2025-11-04 | — | — | CN | disclosed |
| US-12159967-B2 | Nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-03 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240128511-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-04-18 | — | — | US | disclosed |
| US-11942601-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4318719-A2 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4030524-B1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003074008-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003073986-A2 | AMINOALKYLPHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-1996019484-A1 | NOVEL CARBOXAMIDE-DERIVED PHOSPHONATES, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID PHOSPHONATES | PIERRE FABRE MEDICAMENT (FR) | 1996-06-27 | — | — | WO | disclosed |
| US-4278791-A | CORROSION RESISTANCE, WETTING AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
| US-4086208-A | Flame resistant polyesters | TOYO BOSEKI KABUSHIKI KAISHA (JA) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | ALPP, PPIP5K2, ALPI | CYP1A2 1658/4885PPARD 1617/4885NR1I2 1538/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | CYP1A2 2694/4885PPARD 18/4885NR1I2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.